CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade de São Paulo (USP). Instituto de Ciências Biomédicas (ICB) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Dr. João Agostinho Machado-Neto graduated in Biology from the CEUSNP in 2009 and earned a Master's degree in Clinical Medicine from the University of Campinas (Unicamp) in 2011, where he also completed his Ph.D. in Sciences, focusing on Clinical Medicine, in 2015. He then pursued postdoctoral research at the Ribeirão Preto Medical School of the University of São Paulo (FMRP - USP-RP) from 2015 to 2017, with a focus on studying cellular signaling pathways in cancer. Currently, he is an Associate Professor in the Department of Pharmacology at the Institute of Biomedical Sciences, University of São Paulo (ICB - USP). His research focuses on the identification and characterization of antineoplastic compounds and the investigation of the expression, activation, and function of genes involved in altered cellular signaling pathways in cancer, with a particular emphasis on hematological malignancies. His work aims to deeply understand the molecular mechanisms contributing to cancer development and to explore new therapeutic strategies that could have a direct impact on the treatment of these diseases. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Marine Biotechnology studies are of strategic importance for the development of Brazil, a country that has the second largest continuous coastline in the world. In this context, technologies aimed at the sustainable use of marine ecosystem services involving biological, genetic, chemical and ecophysiological resources are essential for meeting the Sustainable Development Goals and other U…
Activation of signaling pathways mediated by tyrosine kinases contributes to the development and progression of hematological malignancies, of which we can highlight myeloproliferative neoplasms (MPN) BCR::ABL1 (Ph+), JAK2V617F and CSF3RT618I positive, and acute myeloid leukemias (AML) FLT3-ITD positive. These mutations have in common the constitutive activation of downstream targets incl…
Hematopoiesis is a highly organized hierarchical process responsible for the production of erythrocytes, leukocytes and platelets. In neoplastic processes, there is a change in regulatory mechanisms, leading to the replacement of healthy cells by neoplastic cells and consequent suppression of normal hematopoiesis. Despite great advances in understanding the biology of hematologic malignan…
Acute leukemias are aggressive hematological malignancies characterized by clonal proliferation with replacement and accumulation of neoplastic cells in the bone marrow, peripheral blood and other organs that suppress normal hematopoiesis. Despite the great advances in understanding the complexity involved in the molecular changes of acute leukemia in recent years, very little has been tr…
Acute leukemias comprise a group of hematological malignancies characterized by the expansion of blasts in bone marrow and peripheral blood, which is mainly due to the loss of differentiation ability of stem cells to functional cells in terminal stage, deregulation of proliferation and resistance to apoptosis. The mortality of adult patients with acute leukemia is very high, making it imp…
Acute myeloid leukemia (AML) is characterized by the clonal expansion of immature myeloid cells, resulting in hematopoietic failure, with symptoms such as anemia and infections. Clinical outcomes are unfavorable, with an estimated overall survival inferior to 25% in five years. AML cells exhibit metabolic reprogramming that promotes dependence on oxidative phosphorylation for ATP producti…
Acute myeloid leukemia (AML), one of the main types of leukemia, is caused by mutations in hematopoietic stem cells located in the bone marrow, peripheral blood and/or other tissues. Over the years, many therapeutic approaches have been developed, such as chemotherapy, hematopoietic stem cell transplantation and target therapy, which came about with the advent of studies that made it poss…
Cancer, one of the most debilitating diseases in the world, occurs due to an exacerbated and disorderly proliferation of cells, which can infiltrate adjacent tissues and spread to other organs. Hepatocellular carcinoma is the most common liver neoplasm, the 5th most common type of cancer and one of the main causes of cancer-related death in the world. The identification of molecules that …
(Only some records are available in English at this moment)
Acute myeloid leukemia (AML) is a heterogeneous malignant hematological neoplasm caused by the accumulation of mutations and molecular alterations in hematopoietic stem cells and corresponds to the highest number of annual deaths from leukemias. The treatment of patients with AML has remained substantially unchanged for over 30 years. Recently, the AML treatment paradigm has been overcome…
Cancer, one of the most debilitating diseases in the world, is characterized by an exacerbated and disordered proliferation of cells, which can invade adjacent tissues and spread to other organs. Cervical carcinoma is the fourth most common cancer in women and treatment options for the advanced stage are limited, leading to high mortality, while gastric cancer is the fifth most common in …
The activation of signaling pathways mediated by tyrosine kinases contributes to the development and progression of hematological neoplasms, of which we can highlight the BCR-ABL1 (Ph+), JAK2V617F and CSF3RT618I positive myeloproliferative neoplasms (MPN), and the FLT3-ITD positive acute myeloid leukemias (AML). These mutations cause constitutive activation of downstream targets, includin…
(Only some records are available in English at this moment)
Acute myeloid leukemia (AML) is one of the most common types of leukemiacharacterized by the accumulation of immature blasts on the bone marrow or peripheralblood. Around one-third of the patients diagnosed with AML have mutations on the FLT3protein, a tyrosine kinase membrane receptor, and amongst those individuals around 25%present the FLT3-ITD mutation, which is a duplication of the in…
Acute leukemias are aggressive neoplasms characterized by clonal proliferation with replacement and accumulation of neoplastic cells (e20%) in the bone marrow and other organs, and when there is the involvement of lymphoblasts they are classified as acute lymphoblastic leukemia (ALL). Despite great advances in understanding the complexity involved in the molecular changes of ALL, very lit…
| 2 / 2 | Ongoing grants |
| 3 / 3 | Completed research grants |
| 8 / 8 | Ongoing scholarships in Brazil |
| 15 / 15 | Completed scholarships in Brazil |
| 1 / 1 | Ongoing scholarships abroad |
| 1 / 1 | Completed scholarships abroad |
| 30 / 30 | All research grants and scholarships |
| Associated processes | |